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Abstract
Objective. To assess the effectiveness, drug survival and safety of tocilizumab compared with TNF-a
inhibitors in clinical practice.
Methods. Patients in the Cohort of Arthritis Biologic Users at Kameda Institute (CABUKI) registry who
were on biologics during July 2003 to October 2010 were included. Remission rates at 6 months,
KaplanMeier drug survival estimates and serious adverse event (SAE) rates were compared.
Results. A total of 247 RA patients were analysed. For first-line biologic users, the 6-month 28-joint DAS
(DAS-28)-ESR remission rates were 66.7% for tocilizumab vs 25.8% for TNF inhibitors (P<0.001, Fisher’s
exact test). This advantage disappeared with the application of the newly suggested Boolean remission
criterion for clinical trials: 0% for tocilizumab vs 8.2% for TNF inhibitors (P=0.367, Fisher’s exact test).
Tocilizumab users in DAS-28-ESR remission had lower mean ESR (3.9mm/h for tocilizumab vs 7.9mm/h
for TNF inhibitors, P=0.026, t-test) and higher mean swollen joint count (2.6 for tocilizumab vs 1.3 for TNF
inhibitors, P=0.036, t-test), thus failing to meet the more stringent Boolean criteria. First- and second-line
tocilizumab users showed similar drug survival and SAE rates compared with TNF inhibitor users.
Conclusion. Tocilizumab had drug survival and safety profiles similar to those of TNF inhibitors in this
Japanese single-centre registry. Tocilizumab was superior to TNF inhibitors when compared at 6 months
by DAS-28-ESR remission. However, the newly suggested Boolean criteria are more appropriate meas-
ures of effectiveness as DAS-28-ESR remission by tocilizumab was mainly due to very low ESR in our
study population.
Key words: Tocilizumab, TNF inhibitors, Rheumatoid arthritis, Benefit, Safety, Treatment outcome, DAS-28,
Boolean remission criteria.
Introduction
RA is a multisystem inflammatory disorder, characterized
by severe synovial involvement, the treatment of which
has advanced substantially in the past two decades.
Use of TNF inhibitors, such as infliximab, etanercept and
adalimumab, results in remission in certain patients in clin-
ical practice [1]. Given their effectiveness, TNF inhibitor
use has become part of formal treatment recommenda-
tions [2, 3]. Despite this, a considerable number of pa-
tients fail to go into remission on TNF inhibitors, and
require other treatments.
Tocilizumab is a humanized mAb against the IL-6 re-
ceptor, blocking its activity through competitive receptor
binding [4]. Tocilizumab monotherapy was compared with
MTX in the Study of Active controlled TOcilizumab
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Inadequate response to methotrexate (SATORI) trial [5]
in Japanese patients refractory to MTX therapy, and
showed effectiveness in disease activity suppression.
Recently, a systematic review by Singh et al. [6] con-
cluded that tocilizumab was effective based on the eight
clinical trials reviewed.
Attempts to compare different biologic agents both dir-
ectly and indirectly have gained popularity in rheuma-
tology. For example, Hetland et al. [1] reported a direct
comparison of three TNF inhibitors using a nationwide
registry in Denmark, finding that etanercept had the best
drug survival rates, while adalimumab showed the best
treatment response. Tocilizumab was not included in the
study. Bergman et al. [7] compared tocilizumab’s ACR
response with that of other biologic agents indirectly via
a systematic literature review. They concluded that tocili-
zumab had similar ACR 20 and ACR 50 response rates,
but a higher ACR 70 response rate. In a more recent
meta-analysis by Salliot et al. [8], clinical trials of biologic
agents used in TNF inhibitor-refractory cases were re-
viewed. Tocilizumab as well as rituximab, abatacept and
golimumab were found to be equally effective. However,
data on comparison of biologic agents in a routine prac-
tice setting are scarce to date.
Clinical experience with tocilizumab has accumulated in
Japan, where it was developed and first approved. In this
Japanese single-centre, registry-based observational
study, we report on the effectiveness, drug survival and
safety of tocilizumab in comparison with TNF inhibitors.
Materials and methods
The present study was conducted at Kameda Medical
Center, a community-based teaching hospital in a rural
area of Japan. Approval of the ethics committee of the
hospital was obtained (Institutional Review Board of
Kameda Medical Center). Individual patient informed con-
sent was not required under Japanese law, as the present
study was purely observational.
The Cohort of Arthritis Biologic Users at Kameda
Institute registry
We enrolled RA patients who started biologic treatment
under our care into the Cohort of Arthritis Biologic Users
at Kameda Institute (CABUKI) registry. This comprehen-
sive database contains information on baseline character-
istics of patients and disease activity at initial and
follow-up visits. Serious adverse events (SAEs), defined
as hospitalization or the need for i.v. antibiotics, were
also recorded. The treating rheumatologist was respon-
sible for data entry. Data were collected from the initiation
of the biologic therapy to the discontinuation of the agent
for any reason for >3 months.
Eligibility criteria
Patients who were clinically diagnosed with RA and trea-
ted with biologics between July 2003 and October 2010
were potentially eligible. Patients were excluded if the
agent of choice was abatacept, as its use in Japan
began towards the end of the inclusion period. Patients
were also excluded if their biologics had been com-
menced at other institutions. Patients were grouped into
first-, second- and third-line biologic groups. The first-line
group was comprised of patients who were biologic naı ¨ve.
Patients in the second- and third-line groups had used
one or two previous biologic agents, respectively.
Effectiveness measures
Effectiveness was compared between the tocilizumab
group and TNF inhibitors-combined group, which com-
prised infliximab, etanercept and adalimumab users, at 6
months by four remission criteria: DAS-28-ESR<2.6,
DAS-28-CRP<2.3 and the Boolean remission criteria for
both clinical practice and trials. The same comparison
was done between first- and second-line tocilizumab
and TNF inhibitor users. As DAS-28-CRP tends to be
lower than DAS-28-ESR, we utilized the cut-off of 2.3 as
suggested by Inoue et al. [9]. The Boolean criteria for clin-
ical trials and practice were announced at the ACR annual
meeting 2010 and recently published [10, 11]. Remission
criteria for clinical trials are defined as tender joint count
(TJC)41, swollen joint count (SJC)41, patient’s global
assessment (PGA)41 out of 10 and CRP41mg/dl.
Boolean criteria without CRP may be used in clinical prac-
tice until better measures become available. For patients
with follow-up duration <6 months, the 6-month data
were supplied using the last observation carried forward
(LOCF) method. Since prominent discrepancy exists be-
tween DAS-28-ESR and Boolean remission criteria, par-
ticularly in the first-line tocilizumab group, we performed
additional comparisons of patients in DAS-28-ESR remis-
sion between the first-line tocilizumab group and the TNF
inhibitors-combined group.
Statistical analyses
Continuous and categorical baseline variables were ana-
lysed using t-test and Fisher’s exact test, respectively. Of
these baseline variables, ones with univariate P<0.2 or
with clinical significance (tocilizumab use, male sex, age
>65 years, current smoking status, RA disease duration,
prednisolone use, MTX use, previous exposure to other
biologics and DAS-28-ESR without PGA) were included in
the models for multivariate analyses for remission, drug
survival and SAE rate. Baseline DAS-28-ESR without PGA
[DAS-28-ESR (three variables)] was used for multivariate
analyses, as PGA was missing in 42 patients [12].
Baseline predictors of DAS-28-ESR and Boolean remis-
sion for clinical trials and practice at 6 months were deter-
mined with logistic regression models. Explanatory variables
included in the Boolean remission prediction models were
tocilizumab use, sex, age >65 years, current smoking
status, RA disease duration, prednisolone use, MTX use,
previous exposure to other biologics and DAS-28-ESR
(three variables) at baseline. DAS-28-ESR remission pre-
diction models were adjusted for these variables plus
baseline lung disease and diabetes. Longitudinal changes
in DAS-28-ESR were compared between the tocilizumab
2094 www.rheumatology.oxfordjournals.org
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mixed models including prednisolone dose and MTX
dose as random effects.
KaplanMeier drug survival estimates of tocilizumab and
TNF inhibitors-combined groups were analysed with a
log-rank test. Baseline predictors of poor drug survival
were determined using multivariable-adjusted Cox regres-
sion models adjusted for tocilizumab use, sex, age >65
years, BMI, current smoking status, RA disease duration,
RF/ACPA positivity, lung disease, diabetes, concomi-
tant autoimmune diseases, prednisolone use, MTX use,
NSAID use, previous exposure to biologic agents and
baseline DAS-28-ESR (three variables).
We also examined the rates of SAEs per 100 person-
years (PY) of drug usage. Analysis by t-test compared
the mean SAE rate (SAE/100PY of drug usage) for each
group. Baseline characteristics associated with SAE were
analysed with linear regression models with the SAE rate
as the response variable. Adjustment was done for base-
line variables included in the Cox regression models, with
the exception of BMI.
All statistical analyses were performed with R version
2.12 (http://www.r-project.org), except for linear mixed
models, for which PASW Statistics version 18 (SPSS
Inc., Chicago, IL, USA) was used. All tests were two-sided
when applicable. P<0.05 was considered statistically
significant.
Results
We identified 255 potentially eligible RA patients who were
or had been on biologics. One patient on abatacept and
seven patients whose biologic agents had been started at
other hospitals were excluded, leaving 247 patients meet-
ing inclusion criteria for the safety and drug survival ana-
lyses. There were 192 first-, 44second- and 11 third-line
biologic users. Seventeen patients without 6-month re-
sponse data were excluded from the effectiveness ana-
lyses (n=17, first-line infliximab 7, first-line etanercept 8,
second-line etanercept 1 and second-line tocilizumab 1).
Baseline characteristics of the overall cohort and first-line
biologic users are shown in Table 1. Mean follow-up dur-
ation, mean MTX dose, prior history of malignancy and
MTX use showed significant differences between the
first-line biologic groups, whereas mean follow-up dur-
ation [tocilizumab group 10.3 (8.7) months vs TNF inhibi-
tors-combined group 18.9 (13.2) months, P=0.015] and
mean age [tocilizumab group 62.9 (10.8) years vs TNF
inhibitors-combined group 53.2 (16.7) years, P=0.030]
differed significantly in second-line tocilizumab (n=22)
and TNF inhibitor users (n=22, infliximab 3, etanercept
17 and adalimumab 2). Characteristics of third-line bio-
logic users did not differ between the tocilizumab (n=7)
and TNF inhibitors-combined group (n=4, infliximab 1
and etanercept 3).
Effectiveness comparison
Comparisons of remission rates at 6 months are shown in
Fig. 1 (n=230: tocilizumab 46, infliximab 92, etanercept 87
and adalimumab 5), demonstrating a statistically
significant difference by DAS-28-ESR remission criteria
only. For first-line biologic users (n=177: tocilizumab 18,
infliximab 88, etanercept 68 and adalimumab 3), remission
rates are shown in Fig. 2. Statistically significant differ-
ences existed in remission rates between the tocilizumab
group and TNF inhibitors-combined group with regards to
DAS-28-ESR and DAS-28-CRP remission criteria, but not
with Boolean criteria. In the additional analysis, tocilizu-
mab users in DAS-28-ESR remission had a significantly
higher SJC and lower ESR compared with TNF inhibitor
users in DAS-28-ESR remission (Table 2).
For second-line biologic users (n=42: tocilizumab 21,
infliximab 3, etanercept 16 and adalimumab 2), remission
rates were 33.3, 14.3, 0 and 0% in the tocilizumab group,
and 28.6, 38.1, 14.3 and 14.3% in the TNF inhibitors-
combined group by DAS-28-ESR, DAS-28-CRP, Boolean
criteria for clinical practice and Boolean criteria for clinical
trials, respectively. No statistically significant difference
was found between the two groups regardless of the
criteria used.
Remission predictors
Male sex was associated with a better chance of remis-
sion by the Boolean criteria for clinical trials [P=0.004;
odds ratio (OR)=6.96, 95% CI 1.91, 28.11] and clinical
practice (P=0.011; OR=4.70, 95% CI 1.42, 16.16).
Using TNF inhibitors-combined as the reference, tocilizu-
mab use was not a negative predictor by either of the
Boolean criteria. Predictors of DAS-28-ESR remission at
6 months were tocilizumab use (P<0.001, OR=4.79,
95% CI 1.95, 12.52), male sex (P=0.009, OR=3.04, 95%
CI 1.33, 7.17), age >65 years (P=0.008, OR=0.29, 95% CI
0.11, 0.70) and baseline DAS-28-ESR (three variables)
(P<0.001, OR=0.53, 95% CI 0.36, 0.74).
In longitudinal analyses of DAS-28-ESR changes with
linear mixed models, first-line tocilizumab users had sig-
nificantly lower DAS-28-ESR (1.25/12 months of drug
usage, P=0.011) compared with first-line TNF inhibitor
users. The same held true for second-line tocilizumab
users (1.26/12 months, P<0.001).
Drug survival and safety
No significant difference was found in drug survival time
as shown in Fig. 3 (P=0.879, log-rank test) between the
tocilizumab group and TNF inhibitors-combined group
(n=247, tocilizumab 47, infliximab 99, etanercept 96 and
adalimumab 5). Between the first-line tocilizumab group
and TNF inhibitors-combined group (n=192, tocilizumab
18, infliximab 95, etanercept 76 and adalimumab 3), there
was also no statistically significant difference (Fig. 4,
P=0.860, log-rank test). At 6 and 12 months, respectively,
69.6 and 59.7% remained on first-line tocilizumab, where-
as 71.5 and 53.2% remained on TNF inhibitors. Reasons
for drug discontinuation in each group were similar. Drug
survival was also comparable (P=0.354, log-rank test) be-
tween the second-line tocilizumab group (n=22; 72.6% at
6 months, 60.5% at 12 months) and TNF inhibitors-
combined group (n=22; 81.8% at 6 months, 76.7% at
12 months), with similar reasons for discontinuation.
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Overall cohort (n=247) First-line users (n=192)
Baseline characteristics
TCZ
(n=47)
TNFi
(n=200)
TCZ
(n=18)
TNFi
(n=174)
Continuous variables, mean (S.D.) P, t-test P, t-test
Follow-up duration, months 9.6 (7.4) 16.8 (15.6) <0.001* 9.4 (6.6) 16.6 (16) 0.001*
Age, year 60.3 (11.4) 57.7 (14.3) 0.179 60.6 (8.9) 58.1 (14) 0.303
BMI
a 23.9 (4.2) 22.9 (3.8) 0.133 22.6 (4.0) 22.8 (3.7) 0.889
RA disease duration, year 8.8 (7.3) 8.1 (9.2) 0.640 9.1 (8.6) 7.9 (9.4) 0.616
Prednisolone dose, mg 7.3 (4.3) 7.0 (4.4) 0.684 7.0 (5.7) 6.8 (4.5) 0.876
MTX dose, mg/week 6.9 (4.7) 7.0 (3.8) 0.894 4.3 (4.0) 6.9 (3.6) 0.015*
DAS-28-ESR (three variables) 4.8 (1.1) 4.9 (1.2) 0.552 4.9 (1.2) 5.0 (1.2) 0.781
DAS-28-ESR (four variables)
b 5.0 (1.2) 5.1 (1.3) 0.503 5.0 (1.3) 5.2 (1.3) 0.660
Categorical variables, % P, Fisher’s exact test P, Fisher’s exact test
Male 19.1 25.0 0.452 22.2 25.9 1.000
Elderly (age >65 year) 36.2 34.5 0.866 38.9 33.9 0.795
Current smoker
c 17.4 16.7 1.000 11.1 16.7 1.000
RF/ACPA positivity 89.4 89.0 1.000 94.4 88.5 0.699
Chronic kidney disease 12.8 7.5 0.250 11.1 7.5 0.637
Lung disease 25.5 27.0 1.000 27.8 25.9 0.786
Heart disease 4.3 3.5 0.682 0.0 3.4 1.000
Diabetes mellitus 21.3 19.5 0.839 11.1 19.5 0.534
Isoniazid prophylaxis 63.8 69.0 0.492 61.1 70.7 0.424
Concomitant autoimmune disease 21.3 15.5 0.383 27.8 14.9 0.178
FM 6.4 6.5 1.000 0.0 6.3 0.604
Prior history of malignancy 10.6 3.5 0.056 22.2 3.4 0.008*
Prednisolone use 91.5 91.0 1.000 83.3 89.7 0.424
MTX use 74.5 85.0 0.089 55.6 85.6 0.004*
NSAIDs use 44.7 56.0 0.194 61.1 56.9 0.806
aNot available in eight patients.
bNot available in 42 patients.
cNot available in 21 patients. *Statistically significant. TCZ:
tocilizumab; TNFi: TNF inhibitors.
FIG.1Remission rates (%) by criteria for toclizumab vs
TNF inhibitor groups (overall cohort). Pract Boolean:
Boolean remission criterion for clinical practice; Trial
Boolean: Boolean remission criterion for clinical trials;
TCZ: tocilizumab; TNFi: TNF inhibitors.
FIG.2Remission rates (%) by criteria for toclizumab vs
TNF inhibitor groups (first-line users). Pract Boolean:
Boolean remission criterion for clinical practice; Trial
Boolean: Boolean remission criterion for clinical trials;
TCZ: tocilizumab; TNFi: TNF inhibitors.
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discontinuation were BMI [P=0.013, hazard ratio
(HR)=1.06 for each 1-point increase in BMI, 95% CI
1.01, 1.11]. In contrast, previous exposure to other bio-
logics (P=0.016, HR=0.52, 95% CI 0.31, 0.88), concomi-
tant autoimmune disease (P=0.042, HR=0.56, 95% CI
0.32, 0.98) and NSAID use (P=0.005, HR=0.57, 95% CI
0.38, 0.84) were associated with decreased risk.
Compared with TNF inhibitors-combined, tocilizumab
use was not associated with changes in risk (P=0.357,
HR=1.30, 95% CI 0.74, 2.27).
Differences in mean SAE rate for each group were not
statistically significant: 43.1/100PY of drug usage for the
tocilizumab group and 35.2/100PY of drug usage for the
TNF inhibitors-combined group (P=0.730, t-test). When
calculated by dividing the total number of SAEs by the
total duration of drug usage, the SAE rates were 15.9/
100PY for the tocilizumab group and 13.9/100PY for
the TNF inhibitors-combined group. No baseline charac-
teristics were associated with a significant increase in SAE
rate. RF/ACPA positivity [P=0.084, regression coefficient
(RC)=54.6/100PY, 95% CI 116.6, 7.4], concomitant
autoimmune disease (P=0.099, RC=46.6/100PY,
95% CI 102.0, 8.8) and NSAIDs use (P=0.062, RC=
3.1/100 PY, 95% CI 80.0, 1.9) were associated with
a non-significant trend towards decreased risk of SAEs.
Tocilizumab use (TNF inhibitors-combined as the refer-
ence) was not a significant predictor (P=0.685,
RC=+11.1/100PY, 95% CI 42.7, 64.9).
The most common SAEs in the TNF inhibitors-
combined group were pneumonia (14 events) followed
by urinary tract infection (UTI) (4 events), worsening of
interstitial lung diseases (3 events), malignancy (3
events) and pulmonary haemorrhage (3 events), whereas
soft-tissue infections (2 events), UTI (2 events) and vascu-
litis (2 events) occurred in the tocilizumab group. One
event of vasculitis and two events of soft-tissue infections
also occurred in the TNF inhibitors-combined group.
Discussion
The present study assessed the effectiveness, drug sur-
vival and safety of tocilizumab in clinical practice com-
pared with TNF inhibitors. In the effectiveness analysis,
we found that first-line tocilizumab achieved higher remis-
sion rates than first-line TNF inhibitor use by both DAS-
28-ESR and DAS-28-CRP remission criteria, but not by
the new Boolean remission criteria. In the drug survival
analysis, tocilizumab was comparable with TNF inhibitors
both in first- and second-line use. In the safety analysis,
SAE rates were similar between the tocilizumab and the
TNF inhibitors-combined groups.
Tocilizumab achieved a higher 6-month remission rate
than TNF inhibitors by DAS-28-ESR remission criterion.
Tocilizumab users also achieved lower DAS-28-ESR
values in the longitudinal analysis. Interestingly, none of
the first-line tocilizumab users in DAS-28-ESR remission
met the Boolean remission criteria. In fact, more patients
in the TNF inhibitor groups were in remission by these new
FIG.4KaplanMeier drug survival estimates for first- and
second-line biologic users. Number at risk in each group
is shown at the bottom. TCZ: tocilizumab; TNFi: TNF
inhibitors.
FIG.3KaplanMeier drug survival estimates for all bio-
logic users. Number at risk in each group is shown at the
bottom. TCZ: tocilizumab; TNFi: TNF inhibitors.
TABLE 2 Comparison of mean values between first-line
tocilizumab and TNF inhibitor users in DAS-28-ESR
remission
DAS-28-ESR components TCZ TNFi P, t-test
TJC (028) 0.7 0.3 0.139
SJC (028) 2.6 1.3 0.036*
PGA (010) 17.3 14.6 0.531
ESR, mm/h 3.9 7.9 0.026*
*Statistically significant. TCZ: tocilizumab; TNFi: TNF
inhibitors.
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Lower ESRs in first-line tocilizumab users in DAS-28-
ESR remission caused this intriguing discrepancy. ESR
was lower by 4mm/h in this group (3.9mm/h) compared
with first-line TNF inhibitor users (7.9mm/h) in DAS-28-ESR
remission. ESR is heavily weighted in DAS-28-ESR [13].
More importantly, its weight rapidly decreases as ESR
approaches zero, which commonly occurs in tocilizumab
users. Thus a 4mm/h decrease in ESR in this range
causes DAS-28-ESR to decrease by approximately
0.49, effectively allowing patients to have an additional
two to three swollen joints and still remain in remission by
DAS-28-ESR criteria. As the Boolean remission criteria
require the SJC to be 41, these first-line tocilizumab users
in DAS-28-ESR remission failed to meet Boolean criteria.
Several groups have reported similar results comparing
DAS-28-ESR remission with remission defined by the
simple disease activity index (SDAI) and the clinical dis-
ease activity index (CDAI) [14, 15] in clinical trials.
Nishimoto et al. [16] reported good correlation between
DAS-28-ESR and SDAI/CDAI in the SATORI study, al-
though remission rates at Week 24 by DAS-28-ESR
(47.2%) and SDAI/CDAI (17.0 and 15.1%, respectively)
showed differences. Smolen et al. [17] reported that toci-
lizumab achieved four times more DAS-28-ESR remission
compared with CDAI remission, whereas TNF inhibitors
achieved two times more DAS-28-ESR remission. They
stated that although this discordance was most prominent
with tocilizumab, it also happened with TNF inhibitors and
MTX. We confirmed the new Boolean remission criteria
are as stringent as SDAI/CDAI remission criteria. The
problematic laxity of the DAS-28-ESR remission criterion,
which affects all biologics, but appears to favour tocilizu-
mab, may be avoided with the use of these new criteria.
The present study also confirmed that the drug survival
of tocilizumab was comparable with the TNF inhibitors,
both in first- and second-line use. The drug survival rate
of tocilizumab was 69.6% at 6 months in first-line users,
whereas72.6%remainedontocilizumabat6monthsinthe
second-line group. This is similar to values reported in the
REtrospective ACTemra Investigation for OptimalNeedsof
RA Patients (REACTION) study [18], in which 6-month drug
survivalratesof78.5%forfirst-line usersand77.6%forthe
TNF inhibitor failure group were observed.
No pneumonia was observed in the tocilizumab group
during the study period, whereas the number of serious
soft-tissue infections was similar between these groups,
even though the tocilizumab group had fewer patients and
a shorter follow-up duration. This might suggest that in-
fections associated with tocilizumab use are different from
those associated with TNF inhibitor use. On the other
hand, Campbell et al. [19] reported that most common
infections occurring with tocilizumab use were skin and
subcutaneous infections and respiratory tract infections,
and similar infection profiles were observed in TNF inhibi-
tor users. Japanese post-marketing surveillance yielded
similar results; respiratory tract infections were the most
common infectious complications, followed by soft-tissue
infections [20]. At this point, special attention to both
pneumonia and soft-tissue infections in tocilizumab
users is required.
The limitations of the present study mainly arise from its
observational design. Channelling or allocation bias [21],
resulting from preferential use of a particular agent in pa-
tients with a better or worse prognosis, should be con-
sidered in the present study. First-line tocilizumab users
were less often on concurrent MTX therapy. It is likely that
treating physicians chose patients who could not tolerate
MTX as candidates for tocilizumab therapy. These
MTX-naı ¨ve patients may have been more likely to respond
to any further treatment compared with MTX-refractory
patients. We addressed this problem with logistic regres-
sion models adjusted for MTX use after which tocilizumab
use was still associated with a higher OR of attaining
DAS-28-ESR remission. This indicates that the higher
DAS-28-ESR remission rates observed in the first-line
tocilizumab group were due to medication rather than pa-
tient selection. Finally, the tocilizumab group was substan-
tially smaller than the TNF inhibitors-combined group and
had a shorter follow-up period. This is likely due to shorter
experience with tocilizumab, approved in Japan in 2008,
compared with TNF inhibitors, which have been in clinical
use since 2003. As clinical experience with tocilizumab
grows, future follow-up studies are warranted.
In conclusion, the present study suggests tocilizumab
has drug survival and safety profiles similar to those of
TNF inhibitors in clinical practice. Although a higher rate
of DAS-28-ESR remission was observed in the tocilizu-
mab group, DAS-28-ESR remission achieved with tocili-
zumab may be different from that achieved with TNF
inhibitors, given that the ESR component of the composite
score was heavily affected by tocilizumab. This problem
may be addressed by using the newly suggested Boolean
remission criteria, which we anticipate will be the pre-
ferred method, along with SDAI and CDAI, in the years
to come. Further studies are needed to clarify the clinical
implications of discrepant remission rates and the validity
of the new remission criteria.
Rheumatology key messages
. Tocilizumab had drug survival and safety profiles
similar to TNF inhibitors.
. DAS-28, but not the Boolean remission rate was
higherwithtocilizumabcomparedwithTNFinhibitors.
. Decreased ESR with tocilizumab might explain the
discordant remission rate.
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